Neurofibromatosis 1

Neurologic Clinics

Volumn 20, Issue 3, 2002, Pages 841-865

  Lynch, Timothy M ^a   Gutmann, David H ^a  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN;

AUTOSOMAL DOMINANT DISORDER; CELL PROLIFERATION; CLINICAL FEATURE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; INCIDENCE; NEUROFIBROMA; NEUROFIBROMATOSIS; OPTIC NERVE GLIOMA; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ADULT; ASTROCYTOMA; BRAIN; BRAIN NEOPLASMS; CHILD; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OPTIC NERVE GLIOMA;

EID: 0036699110     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(01)00019-6     Document Type: Review

References (104)

1. Rubinstein LJ. Pathological features of optic nerve and chiasmatic gliomas. Neurofibromatosis 1988;1:152-58.
2. Hecht F. Recognition of neurofibromatosis before von Recklinghausen. Neurofibromatosis 1989;2:180-84.
3. Von Recklinghausen FD. Ueber die multiplen fibrome der Hautund inhre beziehung zu den multiplen neuromen. Berlin: Hirschwald, 1982.
4. Crowe FW, Schull WJ, Neel JV. A Clinical, Pathological and Genetic Study of Multiple Neurofibromatosis. Springfield, IL: Charles C. Thomas, 1956.
5. Lisch K. Ueber beteiligung der augen, insbesondere das vorkommen von irisknotchen bei der neurofibromatose (Recklinghausen). Augenheilkde 1937;93:137.
6. NIH Consensus Development Conference. Neurofibromatosis conference statement. Arch Neurol 1988;45:575-78.
7. Sergeyev AS. On the mutation rate of neurofibromatosis. Hum Genet 1975;28:129-38.
8. Samuelsson B, Axelsson R. Neurofibromatosis. A clinical and genetic study of 96 cases in Gothenburg. Sweden. Acta Derm Venereol Suppl (Stockh) 1981;95:67-71.
9. Huson SM, Clark D, Compston DAS, et al. A genetic study of von Recklinghausen's neurofibromatosis in south east Wales. I: Prevalence, fitness, mutation rate and effect of parental transmission on severity. J Med Genet 1989;26:704-11.
10. Riccardi VM, Eichner JE. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. Baltimore: Johns Hopkins University Press, 2nd edition, 1986.
11. Burwell RG, James NJ, Johnston DI. Café au lait spots in school children. Arch Dis Child 1982;57:631-32.
12. Benedict PH, Szabo G, Fitzpatrick TB, et al. Melanotic macules in Albright's syndrome and in neurofibromatosis. JAMA 1968;205:618-26.
13. Crowe FW. Axillary freckling as a diagnostic aid in neurofibromatosis. Ann Intern Med 1964;61:1142.
14. Lewis RA, Riccardi VM. von Recklinghausen neurofibromatosis: Incidence of iris harmartomata. Ophthalmology 1981;88:348-54.
15. Lubs M-LE, Bauer MS, Formas ME, et al. Lisch nodules in neurofibromatosis type 1. N Engl J Med 1991;324:1264-66.
16. Friedman JM, Gutmann DH, MacCollin M, Riccardi VM. Neurofibromatosis: Phenotype, natural history and pathogenesis. Baltimore: Johns Hopkins Press; 1999.
17. Korf BR. Plexiform neurofibromas. Am J Med Genet 1999;89:31-37.
18. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist 2000;5:477-85.
19. Thakkar SD, Feigen U, Mautner VF. Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety. Neuroradiology 1999;41:625-9.
20. Waggoner DJ, Towbin J, Gottesman G, et al. A clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet 2000;92:132-5.
21. Huson SM, Harper PS, Compston DAS. von Recklinghausen neurofibromatosis: A clinical and population study in south east Wales. Brain 1988;111:1355-81.
22. King AA, DeBaun MR, Riccardi VM, et al. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 2000;93:388-92.
23. Ferner RE, Lucas JD, O'Doherty MJ, et al. Evaluation of 18-fluorodeoxyglucose positron emission tomography (13-FDG PET) in the detection of malignant peripheral nerve sheath tumors arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000;68:353-7.
24. Thomas JE, Piepgras DG, Scheithauer BW, et al. Neurogenic tumors of the sciatic nerve: A clinicopathologic study of 35 cases. Mayo Clin Proc 1983;58:640-7.
25. Listernick R, Louis D, Packer R, et al. Optic pathway gliomas in children with neurofibromatosis 1: Consensus Statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997;41:143-9.
26. Russell DS, Rubinstein LJ. Pathology of tumours of the nervous system. Baltimore: Williams & Wilkins; 1989.
27. Stern J, DiGiacinto GV, Housepian EM. Neurofibromatosis and optic glioma: clinical and morphological correlations. Neurosurgery 1979;4:524-8.
28. Stern J, Jacobiec FA, Housepian EM. The architecture of optic nerve gliomas with and without neurofibromatosis. Arch Ophthalmol 1980;98:505-11.
29. Listernick R, Charrow J, Greewald MJ, et al. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994;125:63-6.
30. Listernick R, Charrow J, Greewald MJ, et al. Optic Gliomas in children with neurofibromatosis type 1. J Pediatr 1989;114:788-92.
31. Lewis RA, Gerson LP, Axelsson KA, et al. von Recklinghausen neurofibromatosis. II: Incidence of optic gliomata. Ophthalmology 1984;91:929-35.
32. Habiby R, Silverman B, Listernick R, et al. Precocious puberty in children with neurofibromatosis type 1. J Pediatr 1995;126:364-67.
33. Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 1992;10:249-56.
34. Packer RJ, Lange B, Ater J. Carboplatinum and vincristine for progressive low grade gliomas of childhood. J Clin Oncol 1992;11:850-7.
35. Blatt J, Jaffe R, Deutsch, et al. Neurofibromatosis and childhood tumors. Cancer 1986;57:1225-9.
36. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using US death certificates. Am J Human Genet 2001;68:1110-8.
37. Gutmann DH, Gurney JG. Other Malignancies. In: Friedman JM, Gutmann DH, MacCollin M, Riccardi VM. Neurofibromatosis: Phenotype, natural history and pathogenesis. 1999. Baltimore, Johns Hopkins Press.
38. Fernandez-Calvet L, Garcia-Mayor RVG. Incidence of pheochromocytoma in South Galicia. Spain. J Int Med 1994;236:675-7.
39. Kalff V, Shapiro B, Lloyd R, et al. The spectrum of pheochromocytoma in hypertensive patients with neurofibromatosis. Arch Int Med 1982;142:2092-8.
40. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992;15:631-42.
41. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis type 1. Blood 1998;92:267-72.
42. North K, Joy P, Yuille D, et al. Learning difficulties in neurofibromatosis type 1: the significance of MRI abnormalities. Neurology 1994;44:878-83.
43. Denckla MD, Hofman K, Mazzocco MMM, et al. Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am J Med Genet 1996;67:98-102.
44. North K, Joy P, Yuille D, et al. Cognitive function and academic perfomance in children with neurofibromatosis type 1. Dev Med Child Neurol 1995;37:427-36.
45. Hofman KJ, Harris EL, Bryan RN, et al. Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 1994;124:S1.
46. Legius EM, Descheemaeker MJ, Spaepen A, et al. Neurofibromatosis type 1 in childhood: a study of the neuropsychological profile in 45 children. Genet Couns 1994;5:51-60.
47. Mazzocco MMM, Turner JE, Denckla MB, et al. Language and reading deficits associated with neurofibromatosis type 1: evidence for not-so-nonverbal learning disability. Dev Neuropsych 1995;11:503.
48. Mott S, Kkryja PB, Baumgarner T, et al. Neurofibromatosis type 1 (NF1): association between volumes of T2-weighted high intensity signals (UBOs) on magnetic resonance imaging (MRI) and impaired performance on the judgment of line orientation (JLO). Presented at the conjoint meeting of the CNS and ICNA, October 2-8, 1994, San Francisco, CA.
49. Eldridge R, Denckla MB, Bien E, et al. Neurofibromatosis type I (von Recklinghausen's disease): neurologic and cognitive assessment with sibling controls. Am J Dis Child 1989;143:833-7.
50. Eliason MJ. Neurofibromatosis: implications for learning and behavior. J Dev Behav Pediatr 1986;7:175-9.
51. Joy P, Roberts C, North K, et al. Neuropsychological function and MRI abnormalities in Neurofibromatosis type 1. Dev Med Child Neurol 1995;37:906-14.
52. Aoki S, Barkovich AJ, Nishimura K, et al. Neurofibromatosis types 1 and 2: cranial MR findings. Radiology 1989;172:527-34.
53. Bognanno JR, Edwards MK, Lee TA, et al. Cranial MR imaging in neurofibromatosis. Am J Neuroradiol 1988;9:381-8.
54. Dimario FJ, Ramsby G, Greenstein R, et al. Neurofibromatosis type 1: magnetic resonance imaging findings. J Child Neurol 1993;8:32-9.
55. Duffner PK, Cohen ME, Seidel FG, et al. The significance of MRI abnormalities in children with neurofibromatosis. Neurology 1989;39:373-8.
56. Dunn DW, Roos KL. MRI evaluation of learning difficulties and incoordination in neurofibromatosis type 1. Neurofibromatosis 1989;2:1-5.
57. Itoh T, Magnaldi S, White RM, et al. Neurofibromatosis type 1: the evolution of deep gray and white matter MR abnormalities. Am J Neuroradiol 1994;15:1513-9.
58. Sevick RJ, Barkovich AJ, Edwards MSB, et al. Evolution of white matter lesions in neurofibromatosis type 1: MR findings. Am J Radiol 1992;159:171-5.
59. Legius EM, Descheemaeker MJ, Steyaert J, et al. Neurofibromatosis type 1 in childhood: correlation with MRI findings with intelligence. J Neurol Neurosurg Psychiatry 1995;59:638-40.
60. Moore BD, Slopis JM, Schomer D, et al. Neuropsychological significance of areas of high signal intensity on brain magnetic resonance imaging scans of children with Neurofibromatosis. Neurology 1996;46:1660-8.
61. Gutmann DH, Aylsworth A, Carey J, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-7.
62. Huson SM. Recent developments in the diagnosis and management of neurofibromatosis. Arch Dis Child 1989;64:745-9.
63. Holt JF. Neurofibromatosis in children. Am J Roentgenol 1978;130:615-39.
64. Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology 2001;56:1433-43.
65. Hall JG. Review and hypotheses: somatic mosaicism: observations related to clinical genetics. Am J Hum Genet 1988;43:355-63.
66. Happle R. Principles of genetics, mosaicism and molecular biology. In: Harper J, Oranje JM, Rose M, eds. Textbook of pediatric dermatology. Vol. 2. Oxford: Blackwell Science; 2000:1037-1056.
67. Zlotogora J. Germ line mosaicism. Hum Genet 1998;102:381-6.
68. Allanson JE, Upadhyaya M, Watson GH, et al. Watson Syndrome, Is it a subtype of type 1 NF? J Med Genet 1991;28:752-6.
69. Stern HJ, Saal HM, Fain PR, et al. Clinical reliability of type 1 neurofibromatosis: Is there a NF-Noonan Syndrome? J Med Genet 1992;29:184-7.
70. Preiser SA, Davenport CB. Multiple neurofibromatosis (von Recklinghausen disease) and its inheritance. Am J Med Sci 1918;156:507.
71. Hall JG. Possible maternal and hormonal factors in neurofibromatosis. Adv Neurol 1981;29:125-31.
72. Easton DF, Ponder MA, Huson SM, et al. An analysis of variation in expression of neurofibromatosis (NF) type (NF1): Evidence for modifying genes. Am J Hum Genet 1993;53:305-13.
73. Cawthon RM, Weiss M, Xu G, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193-201.
74. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients. Science 1990;249:181-6.
75. Xu G, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62:599-608.
76. Daston MM, Scrable H, Norlund M, et al. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells and oligodendrocytes. Neuron 1992;8:415-28.
77. DeClue JE, Cohen BD, Lowy DR. Identification and characterization of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 1991;88:9914-8.
78. Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 1991;88:9658-62.
79. Nordlund M, Gu X, Shipley MT, et al. Neurofibromin is enriched in the endoplasmic reticulum of CNS neurons. J Neurosci 1993;13:1588-1600.
80. Bollag G, McCormick F. Regulators and effectors of ras proteins. Ann Rev Cell Biol 1991;7:601-32.
81. ras transform cells?. Trends Genet 1991;7:91-5.
82. Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990;63:843-9.
83. Wigler MH. GAPs in understanding ras. Nature 1990;346:696-7.
84. Adari H, Lowy DR, Willumsen BM, et al. Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 1988;240:518-21.
85. Trahey M, Wong G, Halenbeck R, et al. Molecular cloning of two types of GAP complementary DNA from human placenta. Science 1988;242:1697-1700.
86. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-43.
87. Knudson AG. Mutation and Cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
88. Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in tumour cells from type 1 neurofibromatosis patients. Nature 1992;356:713-5.
89. ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992;69:265-73.
90. Lau N, Feldkamp MM, Roncari L, et al. Loss of neurofibromin is associated with activation of ras/MAPK and PIS-K/akt signaling in a neurofibromatosis 1 astrocytoma. J Neuropath Exp Neurol 2000;59:759-67.
91. Kourea HP, Cardon-Cardo C, Dudas M, et al. Expression of p27-Kip and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: The emerging role of p27-Kip in malignant transformation of neurofibromas. Am J Pathol 1999;155:1885-91.
92. Koureau HP, Orlow I, Scheithauer BW, et al. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 1999;155:1855-60.
93. Menon AG, Anderson KM, Riccardi VM, et al. Chromosome 17p deletions and p53 gene mutation associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 1990;87:5435-9.
94. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/pl6 inactivation. Am J Pathol 1999;155:1879-84.
95. Reilly KM, Loisel DA, Bronson RT, et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000;26:109-113.
96. Vogel KS, Klesse LJ, Velasco-Miguel S, et al. Mouse tumor model for neurofibromatosis type 1. Science 1999;286:2176-9.
97. Hewett SJ, Choi DW, Gutmann DH. Increased expression of the neurofibromatosis (NF1) tumor suppressor gene protein, neurofibromin, in reactive astrocytes in vitro. Neuroreport 1995;6:1565-8.
98. Gutmann DH, Donahoe J, Brown T, et al. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropath Exp Neurobiol 2000;26:361-7.
99. Platten M, Giordano MJ, Dirvem CMF, et al. Upregulation of specific NF1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol 1996;149:621-7.
100. Bajenaru ML, Donahoe J, Corral T, et al. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 2001;33:314-23.
101. Gutmann DH, Loehr A, Zhang Y, et al. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 1999;18:4450-9.
102. ras protein farnesyltransferase. Proc Natl Acad Sci USA 1991;88:11368-72.
103. Kinsella BT, Erdman RA, Maltese WA. Posttranslational modification of Ha-ras p21 by farnesyl versus geranylgeranyl isoprenoids is determined by the COOH-terminal amino acid. Proc Natl Acad Sci USA 1991;88:8934-9.
104. Zanca A. Antique illustrations of neurofibromatosis. Int J Dermatol 1980;19:55-8.